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SUMMARY
From February, 1981 to May, 2001, 63 children under 15 y old (ages 2 - 15 y, median = 8 y, mean ± 1 SD = 8 ± 3 y) presenting
70 episodes of Paracoccidioidomycosis were admitted. The main clinical manifestations and laboratory features observed upon
admission were: lymph node enlargement (87.1%), fever (75.7%), weakness (48.6%), pallor (41.4%), hepatomegaly (40%),
splenomegaly (35.7%), anemia (90%), hypergammaglobulinemia (88.5%), eosinophilia (75.5%) and hypoalbuminemia (72.5%).
Moderate to severe malnutrition was detected in 35.7% of the episodes (Gomez’s criterion). Radiographic and technetium studies
showed bone lesions in 20 of the episodes, most of them being multiple lytic lesions, involving both long (70%) and plain bones
(30%). First line treatment consisted of an association of sulfametoxazole-trimethoprin, which was used, exclusively, in 50 episodes.
Follow-up of hemoglobin levels, number of eosinophils in the peripheral blood, albumin and gammaglobulin serum levels revealed
significant sequential improvement one and six months after hospital admission, being quite useful to evaluate treatment effectiveness.
Six patients died (9.3%) and four developed sequelae (6.3%) . In conclusion, the juvenile and disseminated forms can be observed in
about 70% of the episodes of PCM occurring in children younger than 15 y old, most of them presenting with a febrile
lymphoproliferative syndrome associated to anemia, eosinophilia and hypergammaglobulinemia.
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INTRODUCTION
Paracoccidioidomycosis (PCM) is a granulomatous disease caused
by Paracoccidioides brasiliensis. It was originally described by Lutz in
1908 and firstly observed in children by Montenegro, in 191126. PCM is
the most important mycosis of Latin America, the endemic area being
centered in Brazil, especially in the Southern and Southeastern regions4-
5,11,18,23,25
. Approximately 50 cases have already been described in North
America and other countries. All patients had visited or previously lived
in one of the countries where PCM is endemic1,13.
The natural habitat of P. brasiliensis has not yet been defined,
although epidemiological data suggest that the fungus lives in the soil5,8,19.
More than 95% of the cases occur in adults, probably secondary to the
long latency period of PCM, as demonstrated by the nonautochthonous
cases reported outside the endemic areas1.
The lack of published reports about this disease in children2-3,6,9,11,15-
17,22
 prompted us to report our experience with 63 children less than 15 y
old who presented 70 episodes of PCM, admitted to the University Hospital
of the State University of Campinas (UNICAMP), São Paulo, Brazil.
PATIENTS AND METHODS
The hospital records of 63 patients who had a confirmed diagnosis
of PCM, were prospectively collected over a 21-year-period (February,
1981- May, 2001). The following data were analyzed: age, gender,
complaint, signs and symptoms, laboratory features [hemogram, serum
protein electrophoresis, aspartate aminotransferase (AST), alanine
aminotransferase (ALT), gamma glutamyl transpeptidase (γ-GT), serum
bilirubin and bone marrow examination] imaging studies (radiographic,
ultrasonographic and technetium bone scans), treatment regimen,
complications and outcome.
The protein-energy malnutrition diagnosis was established according
to Gomez’s graduation criterion12 that estimates the weight deficit in
relation to age. The National Center for Health Statistics (NCHS) curves
were used for comparison14.
PCM presentation was considered as disseminated when more than
one organ was affected, or if more than two lymph node chains were
involved. If a sole organ and not more than two lymph node chains were
affected the case was diagnosed as the localized form of PCM. Search
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for associated diseases was performed only when the clinical condition
was not improved by the employed treatment.
Hepatic abnormalities associated with PCM were considered when
hepatomegaly was detected by physical examination or by abdominal
ultrasonography, or by an increase in the levels of ALT, AST and γ-GT
enzymes over reference values. The demonstration of the fungus in liver
biopsy samples was also considered as an indicative of positive hepatic
involvement.
Anemia was defined as an hemoglobin level lower than 12.0 g/dl;
eosinophilia as more than 500 cells/mm3 in the peripheral blood;
hypoalbuminemia as albumin levels lower than 3.5 g/dl; and hyper
gammaglobulinemia as gammaglobulin levels higher than 1.8 g/dl.
A database was constructed to evaluate the frequency distribution of
the variables studied, using the SPSS for Windows 10.0 software.
Comparison of variables was evaluated using the Mann-Whitney and
Wilcoxon’s non-parametrical tests. The distribution of hemoglobin levels
and number of eosinophils in the peripheral blood, albuminemia and
gammaglobulinemia are shown as a box and whisker plots. In each plot,
the upper and lower short horizontal lines indicate the maximum and
minimum values observed, respectively. The median, first and third
quartiles of the values of each group correspond to the intermediate,
lower and upper horizontal lines used to construct each rectangle,
respectively. A p value < 0.05 was considered to indicate significance.
RESULTS
Seventy episodes of PCM were diagnosed in 63 children (ages 2 y -
15 y, median = 8 y, mean ± 1 SD = 8 ± 3 y), with a male:female ratio of
1.3:1. When only children older than 12 y old were considered (N = 13),
a male:female ratio of 5.5:1 was observed. Four patients presented more
than one episode of PCM. In 35.7% of the 70 episodes, patients showed
moderate to severe malnutrition (grade II = 24.3% and grade III = 11.4%)
upon admission. Forty-eight children were Caucasians, and there were
no Asian children. By the time diagnosis was established most were
living in urban areas (N = 47/63, 74.6%). Forty-four percent of the
patients came from Campinas’ metropolitan region, 30% from the
southern part of the State of Minas Gerais, and 26% others came from
other cities of the State of São Paulo. More epidemiological data was
not available.
In all 70 episodes, diagnosis was confirmed by the identification of
Paracoccidioides brasiliensis in lymph node biopsy (84%), bone biopsy
(9%) or skin biopsy (7%). Most patients showed disseminated forms
(53/70 episodes, 70%), with localized forms being observed in 17
episodes.
The complaints that prompted children to seek medical care and
motivated their admission had lasted, on average, 60 d (15 d- 1 y, Table
1). There was no significant difference considering the duration of
complaints between the groups of children with disseminated and
localized forms (Mann-Whitney test, p = 0.3).
The main clinical manifestations found at the moment of admission
are summarized in Table 2. Lymph node enlargement was the most
frequent clinical manifestation; in 35 episodes only lymph node
involvement was observed. As complications of lymphatic involvement,
three patients presented intestinal obstruction, and two had protein-
loosing enteropathy, caused by intestinal lymphangiectasy, which
improved with the treatment for PCM. The most common skin lesion
was of the verrucous type, although some children presented lesions
that looked like molluscum contagiosum.
In 45 episodes of PCM, bone involvement was investigated
(radiographic bone survey in 17, technetium bone scan in 14 and both in
14) and it was present in 20, consisting of multiple lytic lesions, in sixteen
of them. Four patients showed a solitary bone lesion in the femur, which
caused their sole clinical manifestation: painful movement of the thigh.
Both long (14/20, 70%) and plain bones (6/20, 30%) were involved.
Among the 14 patients undergoing both radiographic and technetium
investigations, three showed lesions only in the technetium bone scan.
Enlarged hilar lymph nodes were the main findings of chest
radiography (24/64, 37.5%). Only one of the patients showed pulmonary
involvement, characterized by bilateral diffuse heterogeneous opacity.
Abdominal ultrasonography performed in 55 episodes revealed 11 (20%)
normal results; lymph node enlargement (mainly peri-liver, peri-spleen
and mesenteric) in 42 (76.4%), homogeneous hepatomegaly in 33 (60%)
and splenomegaly in 19 (34.5%).
The most frequent laboratory findings at admission were: anemia
63/70 (90%), hyper gammaglobulinemia 62/70 (88.5%), eosinophilia
Table 2
The main clinical manifestations observed at the hospital admission, in 63
children under 15 y old who developed 70 episodes of
Paracoccidioidomycosis
Clinical manifestation Number %
Lymph node enlargement 61 87.1
Fever 53 75.7
Weight loss 53 75.7
Weakness 34 48.6
Pallor 29 41.4
Hepatomegaly 28 40.0
Splenomegaly 25 35.7
Osteoarticular pain or tumefaction 14 20.0
Jaundice 9 12.9
Cutaneous lesions 7 10.0
Lymph node fistulization 7 10.0
Abdominal pain 5 07.1
Table 1
Duration of complaints before hospital admission, in 63 children under 15 y
old who developed 70 episodes of Paracoccidioidomycosis, related to the
number of episodes
Duration of complaint (days) Number of episodes (%)
< 60 43 (61.5)
61 – 120 17 (24.3)
121 – 180 4 (5.7)
181 – 360 6 (8.5)
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53/70 (75.5%) and hypoalbuminemia 50/69 (72.5%). Figure 1 shows
the evolution of those laboratory parameters in the different time points
of the study (admission, one and six months post-admission) in 30
episodes, where complete data was available.
Some patients presented a slight increase of ALT and AST (9/45,
20%), γ-GT (8/26, 30.7%) and direct bilirubinemia (8/18, 44.4%) levels.
Bone marrow examination was performed in eight patients, showing
fungus in five and hypo cellular condition in three.
Associated disease was found in only one child in whom lung
tuberculosis was diagnosed during the second month of treatment of PCM.
Different therapeutic regimens were employed to treat specifically
the PCM: sulfametoxazole-trimethoprin was used in 96% of the patients,
as the sole drug in 50 patients (71.5%) or associated to amphotericin B
(9/70, 13%), ketoconazole (5/70, 7%), amphotericin B and ketoconazole
(2/70, 3%) or itraconazole (1/70, 1.5%). Two patients were treated only
with amphotericin B and one with ketoconazole. The mean duration of
the treatment (attack plus maintenance) was 18 months (from 12 to 36
months). Leucopenia (< 5,000 leucocytes/mm3) secondary to the use of
sulfametoxazole-trimethoprin occurred in 12 episodes, and was controlled
by folinic acid administration, with no need of changing the therapeutic
regimen. Recovery of nutritional status occurred in all cases after
beginning the treatment.
There were six deaths (9.5% of the patients), all of them in patients
with severe disseminated forms of PCM. Five of those patients presented
malnutrition. Deaths occurred between the 2nd and the 28th hospitalization
day (median = 14 d). There was no significant association between duration
of symptoms and lethal outcome (p = 0.5). Five of these patients were
treated with amphotericin B, as the sole drug (N = 2) or associated with
sulfametoxazole-trimethoprin (N = 3). Necropsy (performed in five patients),
confirmed fungus’ dissemination in all patients: lymph nodes, spleen, liver,
bone marrow, bones and skin in all cases; lungs (4/5); small bowel (2/5);
kidneys (1/5); pancreas (1/5); heart (1/5); tongue (1/5); tonsils (1/5) and
testicles (1/5). No other infectious agent or associated complication was
present, suggesting that death was likely caused by the fungal infection.
Fifty patients are being followed in the outpatient clinic; thirty-six
have completed the treatment, while fourteen are still under treatment.
Two of these last patients relapsed after abandoning treatment during its
first semester. Seven patients were lost to follow up after showing an
initial improvement in both clinical and laboratory parameters.
Complications of the disease occurred in four patients (6.3%). Three
developed portal hypertension. In one of them, an associated cholelithiasis
had to be treated by cholecystectomy after the end of the PCM treatment.
Another patient developed a huge splenomegaly associated with severe
hyperesplenism, and had to have its spleen removed six months after the
beginning of the treatment.
DISCUSSION
Although positive skin tests with paracoccidiodin occur with the
same frequency in adult men and women, the clinical form appears to
have a definite preponderance in males (male:female ratio of 15:1). That
discrepancy has been related to the presence of estrogen-dependent
immune factors, which block the transformation of the mycelium-to-
yeast form. The absence of these factors in children may help to explain
why the male:female ratio of clinical PCM is close to 1:15,18,19 in this
group of patients. A higher frequency among male patients above 12 y
old, who had already initiated pubertal development, was also observed
in this study.
Duration of symptoms before the diagnosis and the clinical
manifestations of PCM were similar to other studies2-3,6,9,11,15-17. Most of
the clinical manifestations were related to the reticuloendothelial system,
especially lymph node enlargement, hepatomegaly and splenomegaly.
Severe malnutrition, which may jeopardize cellular immunity, has
been implicated by some into triggering the disease20,29. However, the
low frequency of children with severe malnutrition observed in the present
study and the complete recovery of nutritional status after treatment,
suggest that the malnutrition may be secondary to the PCM.
Hepatic abnormalities associated with PCM occurred in almost half
of the episodes. The increase in γ-GT and direct bilirubin levels may
suggest, in some cases, the occurrence of an obstructive jaundice, caused
by enlargement of the hilar lymph node7.
Despite the characteristics of the bone lesions being similar to those
previously reported6,15-16,28, a more frequent bone involvement was
observed in the present study. This may be related to the use of technetium
bone scan in a great number of cases. As observed, this scan was able to
diagnose small bone lesions that were not detected by conventional
Fig. 1 – Box-plots of: hemoglobin and number of eosinophils in the peripheral blood; albumin
and gammaglobulin serum levels, different time points. T0, 1st day of hospital admission; T1
and T6, one and six months after hospital admission, respectively; NS = not significant; * p
< 0.01 (Wilcoxon test).
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radiology.
As suggested by the necropsy findings, the frequency of pulmonary
parenchyma lesions may be under reported, especially in the disseminated
forms. Although speculative, more accurate data could result from
searching the fungus in the bronchoalveolar lavage.
Bone marrow examination was performed in eight patients who were
initially referred to a pediatric oncology service, with a presumed
diagnosis of leukemia or lymphoma. Although this procedure has helped
to confirm the diagnosis of PCM, it is our belief that it should not be
performed routinely in these cases.
The laboratory findings (anemia, eosinophilia, hypoalbuminemia and
hyper gammaglobulinemia) upon hospital admission did not differ from
elsewhere reported10,15. In addition, the present results show significant
sequential improvement of the laboratory data one and six months after
hospital admission. The follow up with these parameters is simple and
quite useful to evaluate the effectiveness of the treatment.
PCM treatment should last for a long time, since its premature
interruption leads to a high relapse rate. This is demonstrated by the
occurrence of relapse in both children who abandoned treatment during
the first six months, and suggests that the other relapsing cases may be
due to an insufficient period of treatment. However, there is no consensus
concerning the adequate period of treatment for children with PCM,
which may last from six months to two years21,24. The association of
sulfametoxazole-trimethoprin has been considered to be the first option
for the treatment of PCM, since it is well tolerated and associated with
few side effects. The effectiveness of this association is over 80%.
Moreover, it is inexpensive, may be infused intravenously in the severe
forms of PCM, it is easy to administer orally and it is available in public
health services. According to some, failures of treatment with this
association are mostly secondary to poor patient compliance19,24,27,30.
The frequency of deaths herein reported did not differ from the one
observed in other reported series of PCM in children6, despite the use of
amphotericin B and adequate supportive measures in the vary severe
cases. Deaths may be attributed to the severity of the disseminated forms
of PCM in some children, probably immunocompromised by both PCM
and malnutrition20,25,29.
In conclusion, the diagnosis of juvenile and disseminated forms of
PCM should always be considered in children younger than 15 y old,
coming from regions where PCM is endemic and presenting with a febrile
lymphoproliferative syndrome, associated to anemia, hyper
gammaglobulinemia and eosinophilia. Early diagnosis and institution
of appropriate treatment is essential to achieve adequate control of this
disease. Empirical treatment should be considered in severe disseminated
forms, while laboratory studies to confirm PCM are being conducted.
RESUMO
Paracoccidioidomicose em crianças: apresentação clínica,
seguimento e evolução
Foram analisados 70 episódios de Paracoccidioidomicose em 63
crianças com menos de 15 anos de idade (variação de 2 a 15 anos, mediana
= 8 anos, média ± 1 DP = 8 ± 3 anos), no período de fevereiro de 1981
a maio de 2001. As principais manifestações clínicas e alterações
laboratoriais à admissão foram: linfonodomegalia (87,1%), febre
(75,7%), fraqueza (48,6%), palidez (41,4%), hepatomegalia (40,4%),
esplenomegalia (35,7%), anemia (90%), hipergamaglobulinemia
(88,5%), eosinofilia (75,5%) e hipoalbuminemia 72,5%. À admissão,
35,7% das crianças apresentavam desnutrição moderada e grave (critério
de Gómez). Os resultados de radiografia simples e cintilografia óssea
revelaram lesões ósseas em 20 episódios, a maioria constituída de lesões
múltiplas e líticas, envolvendo ossos longos (70%) e planos (30%). A
droga de escolha para o tratamento foi a associação sulfametoxazol-
trimetoprina, sendo empregada isoladamente em 50 episódios. O
seguimento de alguns resultados laboratoriais (dosagem de hemoglobina
e contagem de eosinófilos no sangue periférico, dosagem de albumina e
gamaglobulina séricas) revelou melhora significativa após o 1º e 6º mês
da admissão, sendo muito útil para avaliação da eficácia terapêutica.
Quatro pacientes evoluíram com seqüelas (6,3%) e seis (9,3%) morreram.
Pode-se concluir que as formas juvenil e disseminada da PCM são
prevalentes em crianças menores que 15 anos, ocorrendo em 70% dos
episódios, apresentando-se como uma síndrome linfoproliferativa febril
associada a anemia, eosinofilia e hipergamaglobulinemia.
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